SynthesisESC heart failure2021
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis.
Synthesis in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Late Gadolinium Enhancement by Cardiac Magnetic Resonance and Speckle Tracking Echocardiography in the Evaluation of Cardiac Complications in Chagas Cardiomyopathy: A Systematic Review.Reviews in cardiovascular medicine · 2022Pooled it
- Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta-analysis.ESC heart failure · 2021Pooled it
- Multiparticulate Drug Delivery Systems Preserve the Efficacy of Reduced-Dose Intermittent Benznidazole Therapy in Experimental Chagas Disease.Research square · 2026Article
- Chagas-specific Death and Competing Risk of Mortality in Chile: A Nationwide Retrospective Cohort Study, 2007-2021.Open forum infectious diseases · 2026Article
- Left Atrial Coupling Indexes as New Mortality Predictors in Chronic Chagas Disease.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Cardiac magnetic resonance predictors of adverse outcomes in Chagas cardiomyopathy.Frontiers in cardiovascular medicine · 2026Article
- Pyrazole-Imidazoline Derivative Prevents Cardiac Damage and Mortality in AcutePharmaceuticals (Basel, Switzerland) · 2025Article
- Economic burden of Chagas disease in Brazil: a nationwide cost-of-illness study.Lancet regional health. Americas · 2025Article
- Global longitudinal strain as a predictor of outcomes in chronic Chagas´ cardiomyopathy.PLoS neglected tropical diseases · 2025Article
- Worldwide prevalence of chagas cardiomyopathy-an analysis from the global burden of disease dataset.Infection · 2025Article
- Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Mechanisms behind the high mortality rate in chronic Chagas cardiomyopathy: Unmasking a three-headed monster.European journal of heart failure · 2024Review
- Cardiac involvement in Chagas disease and African trypanosomiasis.Nature reviews. Cardiology · 2024Review
- Global epidemiology of heart failure.Nature reviews. Cardiology · 2024Review
- Advances in the Understanding and Treatment of Chronic Chagas Cardiomyopathy.Cardiology research · 2024Review
- Chagas Disease: Epidemiology, Diagnosis, and Treatment.Current cardiology reports · 2024Review
- Clinical features of Chagas disease progression and severity.Lancet regional health. Americas · 2024Review
- The epidemiology of Chagas disease in the Americas.Lancet regional health. Americas · 2024Review
- Right-Sided Cardiac Thrombosis and Pulmonary Thromboembolism in Chronic Chagas Disease: A Review of Clinical Features and Post-Mortem Examination.Reviews in cardiovascular medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aimed to estimate the annual mortality risk and its determinants in chronic Chagas cardiomyopathy. METHODS AND
resultsWe conducted a systematic search in MEDLINE, Web of Science Core Collection, Embase, Cochrane Library, and LILACS. Longitudinal studies published between 1 January 1946 and 24 October 2018 were included. A random-effects meta-analysis using the death rate over the mean follow-up period in years was used to obtain pooled estimated annual mortality rates. Main outcomes were defined as all-cause mortality, including cardiovascular, non-cardiovascular, heart failure, stroke, and sudden cardiac deaths. A total of 5005 studies were screened for eligibility. A total of 52 longitudinal studies for chronic Chagas cardiomyopathy including 9569 patients and 2250 deaths were selected. The meta-analysis revealed an annual all-cause mortality rate of 7.9% [95% confidence interval (CI): 6.3-10.1; I
conclusionsThe annual mortality risk in chronic Chagas cardiomyopathy is substantial and primarily attributable to cardiovascular causes. This risk significantly increases in patients with low left ventricular ejection fraction and those classified as AHA stages C and C/D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.